Form 4: Director Ross Acquires LMAT Dividend Rights

Lemaitre Vascular Director Bridget A. Ross reported the acquisition of dividend equivalent rights tied to existing equity awards on September 4, 2025.

Summary

• Bridget A. Ross, a Director of Lemaitre Vascular Inc. (LMAT), reported the acquisition of Dividend Equivalent Rights (DERs) on September 4, 2025.
• These DERs accrued on previously granted Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Specifically, 0.4173 DERs accrued on an RSU award granted on December 12, 2022, and 0.4173 DERs accrued on a PSU award granted on December 12, 2022.
• An additional 0.7138 DERs accrued on an RSU award granted on December 8, 2023, and 0.8546 DERs accrued on a PSU award granted on December 8, 2023.
• Furthermore, 0.8697 DERs accrued on an RSU award granted on December 6, 2024.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock and vests proportionately with its underlying award.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged schedule for the acquisition of these rights.

Sentiment

Score: 6

Explanation: The filing reports a routine, non-discretionary accrual of equity-linked rights by a director, which is a standard part of compensation. While not a direct stock purchase, it signifies continued alignment with shareholder interests through long-term incentive plans, contributing to a neutral-to-slightly positive sentiment.

Positives

• The acquisition of dividend equivalent rights by a director indicates continued participation in the company's equity compensation plans, aligning insider interests with shareholders.
• The use of a Rule 10b5-1(c) plan demonstrates a structured and pre-planned approach to equity transactions, enhancing transparency and reducing concerns about opportunistic trading.

Negatives

• The reported transactions are accruals of rights, not direct open-market purchases of common stock, which would typically signal stronger insider confidence.

Future Outlook

The dividend equivalent rights will vest proportionately with their underlying Restricted Stock Unit and Performance Share Unit awards, aligning the director's future compensation with the company's performance and stock appreciation.

Industry Context

Form 4 filings are standard regulatory disclosures for insider transactions across all industries. The use of equity-based compensation, including RSUs, PSUs, and dividend equivalent rights, is a common practice in the medical device industry and broader corporate landscape to incentivize and retain key personnel, including directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights aligns the director's financial interests with those of shareholders, as the value of these rights is tied to the company's common stock and its performance.
• Employees: The use of equity compensation plans, as evidenced by these awards, is a common practice that can contribute to employee retention and motivation, though this specific filing pertains to a director.

Next Steps

• The dividend equivalent rights will vest in accordance with the vesting schedules of the underlying Restricted Stock Unit and Performance Share Unit awards.

Key Dates

Recommendation

This Form 4 filing details a routine accrual of dividend equivalent rights by a director as part of their existing equity compensation. It does not represent a discretionary open-market purchase or sale of stock, nor does it contain new information regarding the company's operational performance or strategic direction. Therefore, it does not provide a basis for changing an investment recommendation for LMAT.

Keywords

Lemaitre Vascular, LMAT, Bridget A Ross, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Equity Compensation, Director Compensation, Rule 10b5-1